-
-
-
-
-
-
-
GRI Bio raises $6.5 million, extends cash runway into Q1 2027
-
-
-
-
-
-
-
GRI Bio reports positive immune profiling data from IPF drug trial
-
-
-
-
-
-
-
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
-
-
-
-
-
-
-
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
-
-
-
-
-
-
-
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
-
-
-
-
-
-
-
GRI Bio (GRI) Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
-
-
-
-
-
-
-
GRI Bio Announces Reverse Stock Split
-
1,160,150 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

